5 recruiting, 1 completed, 1 suspended. 7 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Recruiting 5, Completed 1, Suspended 1 |
| Phase 2 | 2 | Recruiting 2 |
Follow CX 5461: new trials by email Literature Review of CX 5461 trials Research Report on CX 5461
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene Biopsy Procedure, Biospecimen Collection, Computed Tomography - Burkitt Lymphoma, Double-Expressor Lymphoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 50 | 2027-01-11 | 2026-10-14 |
| Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer Biopsy Procedure, Biospecimen Collection, Echocardiography Test - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Recruiting | National Cancer Institute (NCI) | 36 | 2026-10-06 | 2026-10-16 |
| Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer Biopsy Procedure, Biospecimen Collection, Cemiplimab - Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 86 | 2026-08-10 | 2026-09-09 |
| Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Malignant Solid Neoplasm | Phase 1 | Recruiting | National Cancer Institute (NCI) | 40 | 2025-07-01 | 2026-09-16 |
| Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer Pidnarulex, Talazoparib - Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 1 | Suspended | Peter MacCallum Cancer Centre, Australia | 48 | 2022-10-21 | 2023-12-11 |
| Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation CX-5461 - Advanced Solid Tumor | Phase 1 | Recruiting | Senhwa Biosciences, Inc. | 52 | 2021-09-08 | 2026-06-08 |
| A Phase I Study of CX5461 CX5461 - Cancer | Phase 1 | Completed | Canadian Cancer Trials Group | 41 | 2016-06-13 | 2023-08-04 |
Breast Neoplasms (2) · Neoplasm Metastasis (2) · Burkitt Lymphoma (1) · Colorectal Neoplasms (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1) · Triple Negative Breast Neoplasms (1)
National Cancer Institute (NCI) (4) · Canadian Cancer Trials Group (1) · Peter MacCallum Cancer Centre, Australia (1) · Senhwa Biosciences, Inc. (1)
United States (5) · Canada (2) · Australia (1)
Filipa Lynce (1) · Jason Huang, MD (1) · Jibran Ahmed (1) · John Hilton (1) · Karen Gelmon (1) · Sami Ibrahimi (1) · Shahneen Sandhu (1) · Wells A Messersmith (1)
UM1CA186689 (1), UM1CA186691 (1), UM1CA186709 (1)